J.M. Forbes & Co’s TG Therapeutics TGTX Stock Holding History

J.M. Forbes & Co’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,800	Closed	-$210K	–	104
2020 Q2	$210K	Hold	10,800	–	–	0.04%	90
2020 Q1	$106K	Hold	10,800	–	–	0.02%	84
2019 Q4	$120K	Hold	10,800	–	–	0.02%	102
2019 Q3	$61K	Hold	10,800	–	–	0.01%	98
2019 Q2	$93K	Hold	10,800	–	–	0.02%	97
2019 Q1	$87K	Hold	10,800	–	–	0.02%	94
2018 Q4	$44K	Buy	+10,800	New	+$53.7K	0.01%	95

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

J.M. Forbes & Co's TGTX Position: Q3 2020 in Review

J.M. Forbes & Co sold out of TG Therapeutics (TGTX) in Q3 2020, closing a stake of 10,800 shares — an estimated $210K sold.

J.M. Forbes & Co first reported a position in TGTX in Q4 2018 and held it in 7 quarters. The position peaked at $210K in Q2 2020. 181 funds tracked by Wall St. Rank hold TGTX as of Q3 2020.

J.M. Forbes & Co reported no remaining TG Therapeutics position as of Q3 2020 after selling out during the quarter.
J.M. Forbes & Co sold 10,800 TG Therapeutics shares in Q3 2020, an estimated $210K.
J.M. Forbes & Co first reported a position in TG Therapeutics in Q4 2018 and held it in 7 quarters.
J.M. Forbes & Co's TG Therapeutics position peaked at $210K in Q2 2020.
181 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2020.

Based on J.M. Forbes & Co's 13F filing for Q3 2020, filed 13 Nov 2020.